Xiaodian Sun

University of Miami — United States

Immunology and Microbiology · Life Sciences

10h-index249citations85works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(41), Cancer Immunotherapy and Biomarkers(36), Pancreatic and Hepatic Oncology Research(23), Gastric Cancer Management and Outcomes(18), Gastrointestinal Tumor Research and Treatment(18)

Publications85 total

Supplementary Table S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Table S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S4 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Table S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S4 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Data from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Data from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S5 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Table S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S5 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Supplementary Figure S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
2024Open Access
Data from Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
2024Open Access
Supplementary Figure S5 from Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Yuguang Ban(35), Jashodeep Datta(22), Iago De Castro Silva(22), Siddharth Mehra(22), Samara P. Singh(22), Nagaraj S. Nagathihalli(22), Nipun B. Merchant(22), Austin R. Dosch(21), Anna Bianchi(21), Vanessa T. Garrido(21), Zhiqun Zhou(21), Andrew Adams(21), Haleh Amirian(21), Edmond W. Box(21), Farah Ballout(12), Heng Lu(12), Nadeem S. Bhat(12), Lei Chen(12), Dunfa Peng(12), Zheng Chen(12)